XML 9 R2.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 6,755 $ 5,530
Short-term investments 18,955 5,708
Prepaid expenses and other current assets 894 367
Total current assets 26,604 11,605
Property and equipment, net 153 167
Other assets 377 413
Total assets 27,134 12,185
Current liabilities:    
Accounts payable 1,535 1,419
Accrued clinical trial costs 1,000 1,141
Accrued other 1,752 1,468
Total current liabilities 4,287 4,028
Warrant liability 5,600 0
Total liabilities 9,887 4,028
Commitments and contingencies (Note 9)
Stockholders' equity    
Preferred stock, $0.0001 par value; 10,000,000 shares and no shares authorized at March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 0 0
Common stock, $0.0001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 10,740,115 and 5,754,505 issued and outstanding at March 31, 2024 and December 31, 2023, respectively 3 1
Additional paid-in capital 163,195 154,218
Accumulated deficit (145,934) (146,064)
Accumulated other comprehensive income (loss) (17) 2
Total stockholders' equity 17,247 8,157
Total liabilities and stockholders' equity $ 27,134 $ 12,185